{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:07Z","timestamp":1792787887418,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":99,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Joint TCM Science & Technology Projects of National Demonstration Zones for Comprehensive TCM Reform","award":["GZY-KJS-ZJ-2025-055"],"award-info":[{"award-number":["GZY-KJS-ZJ-2025-055"]}]},{"name":"Hangzhou Municipal Health Science and Technology Key Project","award":["ZD20240019"],"award-info":[{"award-number":["ZD20240019"]}]},{"name":"The Zhejiang Provincial Key R&D Program (\u201cLingyan\u201dProject) of the Zhejiang Provincial Department of Science and Technology","award":["2025C02191"],"award-info":[{"award-number":["2025C02191"]}],"id":[{"id":"https:\/\/ror.org\/03rbw2w25","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elderly patients with non-dialysis chronic kidney disease have high cardiorenal risk. SGLT2 inhibitors are considered to potentially provide combined renal and cardiac benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate renal and cardiovascular outcomes and safety of SGLT2 inhibitors in patients aged\u2009\u2265\u200965 years with non-dialysis chronic kidney disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized controlled trials from database inception to 2025-7-18 were systematically searched, and trials enrolling non-dialysis chronic kidney disease and reporting a\u2009\u2265\u200965-year subgroup were included. The primary outcome was an adverse renal composite endpoint, and the key secondary outcome was a composite of cardiovascular death or heart failure hospitalization. Safety focused on genital mycotic infections and volume depletion\/hypotension, and acute kidney injury (AKI) and diabetic ketoacidosis (DKA) were summarized descriptively. Random-effects models based on log HR or RR (REML, Hartung\u2013Knapp) were used, pre-specified sensitivity analyses were performed, and the certainty of evidence was assessed using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three double-blind trials including 5,831 patients aged\u2009\u2265\u200965 years were included. SGLT2 inhibitors reduced the risk of the adverse renal composite endpoint (HR\u2009=\u20090.68, 95% CI 0.52\u20130.89; I\u00b2=29.98%), and the risk of the composite of cardiovascular death or heart failure hospitalization (HR\u2009=\u20090.74, 95% CI 0.64\u20130.86; I\u00b2=35.53%). For safety, the risk of genital mycotic infections was increased (RR\u2009=\u20092.40, 95% CI 1.96\u20132.94; I\u00b2=23.85%), and the risk of volume depletion\/hypotension was also increased (RR\u2009=\u20091.28, 95% CI 1.09\u20131.50; I\u00b2=0.00%); no signal of increased AKI was observed; DKA was very rare. GRADE rated the certainty of evidence as high for the renal outcome and moderate for the heart failure-related outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients aged\u2009\u2265\u200965 years with non-dialysis chronic kidney disease, SGLT2 inhibitors added to standard therapy achieve dual renal and cardiovascular benefits with a manageable safety profile, supporting their structured use with stratified monitoring. It is recommended that SGLT2 inhibitors be routinely included in treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-06248-z","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:25:05Z","timestamp":1783563905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renal and cardiovascular outcomes and safety of SGLT2 inhibitors in patients aged\u2009\u2265\u200965 years with non-dialysis chronic kidney disease: a systematic review and meta-analysis of subgroup-level estimates derived from randomized trials"],"prefix":"10.1186","volume":"26","author":[{"given":"Ziyang","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfa","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caifeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"6248_CR1","doi-asserted-by":"publisher","unstructured":"Brady BM, Suffoletto JA, Sankary R, Chertow GM. Chronic kidney disease in older adults: challenges and opportunities for the primary care provider. BMC Prim Care. 2024;25(1):388. Published 2024 Nov 1. https:\/\/doi.org\/10.1186\/s12875-024-02638-4","DOI":"10.1186\/s12875-024-02638-4"},{"issue":"4","key":"6248_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/geriatrics10040104","volume":"10","author":"M Jarocki","year":"2025","unstructured":"Jarocki M, Green S, Wu HHL, Chinnadurai R. Cardiorenal Syndrome in the Elderly: Challenges and Considerations. Geriatr (Basel). 2025;10(4):104. https:\/\/doi.org\/10.3390\/geriatrics10040104. Published 2025 Aug 4.","journal-title":"Geriatr (Basel)"},{"issue":"5","key":"6248_CR3","doi-asserted-by":"publisher","first-page":"sfaf128","DOI":"10.1093\/ckj\/sfaf128","volume":"18","author":"C Zoccali","year":"2025","unstructured":"Zoccali C, Levin A, Mallamaci F, Giugliano R, De Caterina R. Advanced chronic kidney disease coexisting with heart failure: navigating patients\u2019 management. Clin Kidney J. 2025;18(5):sfaf128. https:\/\/doi.org\/10.1093\/ckj\/sfaf128. Published 2025 May 2.","journal-title":"Clin Kidney J"},{"issue":"4","key":"6248_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3803\/EnM.2023.1764","volume":"38","author":"ES Koh","year":"2023","unstructured":"Koh ES, Kim GH, Chung S. Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis. Endocrinol Metab (Seoul). 2023;38(4):359\u201372. https:\/\/doi.org\/10.3803\/EnM.2023.1764.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"6248_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1159\/000545622","volume":"15","author":"M Wang","year":"2025","unstructured":"Wang M, Zuo L. Cardiorenal Benefits of SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Concomitant Hypertension. Cardiorenal Med. 2025;15(1):496\u2013509. https:\/\/doi.org\/10.1159\/000545622.","journal-title":"Cardiorenal Med"},{"issue":"15","key":"6248_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"1","key":"6248_CR7","doi-asserted-by":"publisher","first-page":"afad254","DOI":"10.1093\/ageing\/afad254","volume":"53","author":"R Aldafas","year":"2024","unstructured":"Aldafas R, Crabtree T, Alkharaiji M, Vinogradova Y, Idris I. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age Ageing. 2024;53(1):afad254. https:\/\/doi.org\/10.1093\/ageing\/afad254.","journal-title":"Age Ageing"},{"issue":"2","key":"6248_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"EMPA-KIDNEY The","year":"2023","unstructured":"The EMPA-KIDNEY, Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"2","key":"6248_CR9","doi-asserted-by":"publisher","first-page":"sfae380","DOI":"10.1093\/ckj\/sfae380","volume":"18","author":"S Liabeuf","year":"2024","unstructured":"Liabeuf S, Minutolo R, Floege J, Zoccali C. The use of SGLT2 inhibitors and GLP-1 receptor agonists in older patients: a debate on approaches in CKD and non-CKD populations. Clin Kidney J. 2024;18(2):sfae380. https:\/\/doi.org\/10.1093\/ckj\/sfae380. Published 2024 Dec 2.","journal-title":"Clin Kidney J"},{"key":"6248_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16. Published 2007 Jun 7.","journal-title":"Trials"},{"key":"6248_CR11","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"7650","key":"6248_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"1","key":"6248_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/sim.2528","volume":"26","author":"MJ Bradburn","year":"2007","unstructured":"Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26(1):53\u201377. https:\/\/doi.org\/10.1002\/sim.2528.","journal-title":"Stat Med"},{"issue":"9","key":"6248_CR14","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","volume":"46","author":"SC Naaman","year":"2023","unstructured":"Naaman SC, Bakris GL. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care. 2023;46(9):1574\u201386. https:\/\/doi.org\/10.2337\/dci23-0030.","journal-title":"Diabetes Care"},{"issue":"10","key":"6248_CR15","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/dom.14108","volume":"22","author":"C Mantsiou","year":"2020","unstructured":"Mantsiou C, Karagiannis T, Kakotrichi P, et al. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2020;22(10):1857\u201368. https:\/\/doi.org\/10.1111\/dom.14108.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6248_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/circulationaha.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Heerspink HJL, Vart P, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024;149(6):450\u201362. https:\/\/doi.org\/10.1161\/circulationaha.123.067584.","journal-title":"Circulation"},{"issue":"4","key":"6248_CR17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","volume":"33","author":"T Sen","year":"2021","unstructured":"Sen T, Heerspink HJL. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab. 2021;33(4):732\u20139. https:\/\/doi.org\/10.1016\/j.cmet.2021.02.016.","journal-title":"Cell Metab"},{"issue":"1","key":"6248_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","volume":"97","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020;97(1):202\u201312. https:\/\/doi.org\/10.1016\/j.kint.2019.09.013.","journal-title":"Kidney Int"},{"key":"6248_CR19","doi-asserted-by":"publisher","unstructured":"Hou YC, Zheng CM, Yen TH, Lu KC. Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. Int J Mol Sci. 2020;21(21):7833. Published 2020 Oct 22. https:\/\/doi.org\/10.3390\/ijms21217833","DOI":"10.3390\/ijms21217833"},{"issue":"6","key":"6248_CR20","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1053\/j.ajkd.2021.09.015","volume":"79","author":"M Zhuo","year":"2022","unstructured":"Zhuo M, Paik JM, Wexler DJ, Bonventre JV, Kim SC, Patorno E. SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes. Am J Kidney Dis. 2022;79(6):858\u2013e8671. https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.015.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"6248_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","volume":"335","author":"BL Neuen","year":"2026","unstructured":"Neuen BL, Fletcher RA, Anker SD, et al. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis. JAMA. 2026;335(3):233\u201344. https:\/\/doi.org\/10.1001\/jama.2025.20834.","journal-title":"JAMA"},{"issue":"13","key":"6248_CR22","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","volume":"330","author":"ME Grams","year":"2023","unstructured":"Grams ME, Coresh J, Matsushita K, et al. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis. JAMA. 2023;330(13):1266\u201377. https:\/\/doi.org\/10.1001\/jama.2023.17002.","journal-title":"JAMA"},{"issue":"37","key":"6248_CR23","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"issue":"1 Suppl 1","key":"6248_CR24","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","volume":"48","author":"Chronic Kidney Disease and Risk Management","year":"2025","unstructured":"Chronic Kidney Disease and Risk Management. Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S239\u201351. https:\/\/doi.org\/10.2337\/dc25-S011.","journal-title":"Diabetes Care"},{"issue":"24","key":"6248_CR25","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"3","key":"6248_CR26","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/ehf2.15223","volume":"12","author":"MV Mariani","year":"2025","unstructured":"Mariani MV, Lavalle C, Palombi M, et al. SGLT2i reduce arrhythmic events in heart failure patients with cardiac implantable electronic devices. ESC heart Fail. 2025;12(3):2125\u201333. https:\/\/doi.org\/10.1002\/ehf2.15223.","journal-title":"ESC heart Fail"},{"issue":"4","key":"6248_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/kidneydial4040016","volume":"4","author":"A Cersosimo","year":"2024","unstructured":"Cersosimo A, Drera A, Adamo M, et al. Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review. Kidney and Dialysis. 2024;4(4):184-202. https:\/\/doi.org\/10.3390\/kidneydial4040016.","journal-title":"Compr Rev"},{"issue":"6","key":"6248_CR28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2459\/jcm.0000000000001733","volume":"26","author":"A Cersosimo","year":"2025","unstructured":"Cersosimo A, Amore L, Cimino G, et al. Impact of SGLT2 inhibitors on endothelial function and echocardiographic parameters in dilated cardiomyopathy. J Cardiovasc Med (Hagerstown Md). 2025;26(6):284\u201396. https:\/\/doi.org\/10.2459\/jcm.0000000000001733.","journal-title":"J Cardiovasc Med (Hagerstown Md)"},{"key":"6248_CR29","doi-asserted-by":"publisher","first-page":"800490","DOI":"10.3389\/fphar.2022.800490","volume":"13","author":"J Tang","year":"2022","unstructured":"Tang J, Ye L, Yan Q, Zhang X, Wang L. Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism. Front Pharmacol. 2022;13:800490. https:\/\/doi.org\/10.3389\/fphar.2022.800490.","journal-title":"Front Pharmacol"},{"key":"6248_CR30","doi-asserted-by":"publisher","unstructured":"Piperis C, Marathonitis A, Anastasiou A et al. Multifaceted Impact of SGLT2 Inhibitors in Heart Failure Patients: Exploring Diverse Mechanisms of Action. Biomedicines. 2024;12(10):2314. Published 2024 Oct 11. https:\/\/doi.org\/10.3390\/biomedicines12102314","DOI":"10.3390\/biomedicines12102314"},{"issue":"4","key":"6248_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):422\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031.","journal-title":"J Am Coll Cardiol"},{"key":"6248_CR32","doi-asserted-by":"publisher","first-page":"1388591","DOI":"10.3389\/fnut.2024.1388591","volume":"11","author":"S Duan","year":"2024","unstructured":"Duan S, Ma Y, Lu F, et al. High sodium intake and fluid overhydration predict cardiac structural and functional impairments in chronic kidney disease. Front Nutr. 2024;11:1388591. https:\/\/doi.org\/10.3389\/fnut.2024.1388591. Published 2024 May 27.","journal-title":"Front Nutr"},{"key":"6248_CR33","doi-asserted-by":"publisher","first-page":"100933","DOI":"10.1016\/j.eclinm.2021.100933","volume":"36","author":"R Cardoso","year":"2021","unstructured":"Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine. 2021;36:100933. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100933. Published 2021 Jun 5.","journal-title":"EClinicalMedicine"},{"issue":"10","key":"6248_CR34","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/ejhf.2334","volume":"23","author":"M Packer","year":"2021","unstructured":"Packer M, Zannad F, Butler J, et al. Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. Eur J Heart Fail. 2021;23(10):1798\u20139. https:\/\/doi.org\/10.1002\/ejhf.2334.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"6248_CR35","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney Int Rep. 2022;7(7):1463\u201376. https:\/\/doi.org\/10.1016\/j.ekir.2022.04.094. Published 2022 May 5.","journal-title":"Kidney Int Rep"},{"issue":"8","key":"6248_CR36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2215\/CJN.17621120","volume":"16","author":"BF Palmer","year":"2021","unstructured":"Palmer BF, Clegg DJ. Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. Clin J Am Soc Nephrol. 2021;16(8):1284\u201391. https:\/\/doi.org\/10.2215\/CJN.17621120.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"6248_CR37","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","volume":"106","author":"DS Lin","year":"2021","unstructured":"Lin DS, Lee JK, Chen WJ. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals. J Clin Endocrinol Metab. 2021;106(7):2133\u201345. https:\/\/doi.org\/10.1210\/clinem\/dgab274.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06248-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06248-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06248-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:02:03Z","timestamp":1792152123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06248-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6248"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06248-z","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"931"}}